CAJ | 학술논문

目的观察前列金丹治疗良性前列腺增生(benign prostatic hyperplasia,BPH)合并Ⅲ型前列腺炎-慢性非细菌性前列腺炎/慢性骨盆疼痛综合征(chronic nonbacterial prostatitis/chronic pelvic pain syndrome,CNBP/CPPS)的临床效果.方法采用双盲临床研究,将100例BPH合并CNBP/CPPS患者完全随机分为研究组和对照组,各50例.研究组采用前列金丹治疗,对照组采用安慰剂治疗.评价2组治疗3个月后的国际前列腺症状评分(international prostate symptom score,IPSS)、慢性前列腺炎症状评分(the NIH chronic prostatitis symptom index,NIH-CPSI)、最大尿流率、残余尿及前列腺液常规(EPS)中WBC计数.结果治疗3个月后,研究组和对照组IPSS评分从治疗前的(12.6±2.5)分和(12.4±2.4)分降至(10.3±2.2)分和(12.1±2.5)分,研究组治疗前后比较差异有统计学意义(P＜0.05);CPSI评分从治疗前的(23.0±5.9)分和(23.9±6.0)分降至(16.6±4.5)分和(22.7±5.9)分,研究组治疗后比较差异有统计学意义(P＜0.05).研究组治疗后的最大尿流率增加,残余尿及前列腺液中WBC计数减少,治疗前后差异有统计学意义(P＜0.05).结论 BPH合并CNBP/CPPS患者给予前列金丹治疗能使症状明显改善.
목적 관찰전렬금단치료량성전렬선증생(benign prostatic hyperplasia,BPH)합병Ⅲ형전렬선염-만성비세균성전렬선염/만성골분동통종합정(chronic nonbacterial prostatitis/chronic pelvic pain syndrome,CNBP/CPPS)적림상효과.방법 채용쌍맹림상연구,장100례BPH합병CNBP/CPPS환자완전수궤분위연구조화대조조,각50례.연구조채용전렬금단치료,대조조채용안위제치료.평개2조치료3개월후적국제전렬선증상평분(international prostate symptom score,IPSS)、만성전렬선염증상평분(the NIH chronic prostatitis symptom index,NIH-CPSI)、최대뇨류솔、잔여뇨급전렬선액상규(EPS)중WBC계수.결과 치료3개월후,연구조화대조조IPSS평분종치료전적(12.6±2.5)분화(12.4±2.4)분강지(10.3±2.2)분화(12.1±2.5)분,연구조치료전후비교차이유통계학의의(P＜0.05);CPSI평분종치료전적(23.0±5.9)분화(23.9±6.0)분강지(16.6±4.5)분화(22.7±5.9)분,연구조치료후비교차이유통계학의의(P＜0.05).연구조치료후적최대뇨류솔증가,잔여뇨급전렬선액중WBC계수감소,치료전후차이유통계학의의(P＜0.05).결론 BPH합병CNBP/CPPS환자급여전렬금단치료능사증상명현개선.
Objective To observe the influence of Qianliejindan in the treatment of the benign prostatic hyperplasia(BPH) with chronic nonbacterial prostatitis/chronic pelvic pain syndrome(CNBP/CPPS).Methods All 100 patients with BPH and CNBP/CPPS were randomly allocated to treatment group and control group in a doubleblind clinic trial.Treatment group was received Qianliejindan while control group was received placebo.After treatment for 3 months,the evaluating indexes included IPSS,NIH-CPSI,peak urinary flow rate,postvoid residual (PVR) volume and WBC count in EPS were evaluated.Results Three months after treatment,the IPSS scores of treatment group and control group decreased from ( 12.6 ± 2.5) and ( 12.4 ± 2.4) to ( 10.3 ± 2.2 ) and ( 12.1 ±2.5 ),and there was significant difference in treatment group( P ＜ 0.05) ; the CPSI scores decreased from(23.0 ±5.9 ) and ( 23.9 ± 6.0) to ( 16.6 ± 4.5 ) and (22.7 ± 5.9),and there was significant difference in treatment group ( P ＜ 0.05 ) ; the peak urinary flow rate after treatment in treatment group increased,PVR and WBC count in EPS decreased,(P ＜ 0.05 ).Conclusion The treatment group has most satisfactory improvements compared with the control group during the study.